iLASIK vision correction combines AMO technologies

Article

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision.

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision (iLASIK vision correction).

The iLASIK procedure is a consumer-facing brand platform that communicates the advantage of two of the company's technologies: femtosecond flap creation technology (IntraLase FS) and custom laser vision correction (Advanced CustomVue). The company presented the re-branded LASIK procedure during a user group meeting at the Hilton Riverside Hotel here prior to the American Academy of Ophthalmology annual meeting.

According to Ron Bache, global vice president of marketing, AMO refractive surgery, the procedure:

•Provides one integrated platform that features advanced technology at every step.

•Can be actively marketed to all segments of "Generation i" (college students, baby boomers, and even fighter pilots).

•Establishes the company as a committed partner that is making an unmatched investment in LASIK.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.